Administration of pigment epithelium-derived factor delivered by adeno-associated virus inhibits blood–retinal barrier breakdown in diabetic rats

Hai Yu,1,2 Lei Chen,1 Jing Jiang1

1Department of Ophthalmology, First affiliated Hospital of China Medical University, Shenyang, Liaoning, China; 2Department of Ophthalmology, General Hospital of Shenyang Military Command, Shenyang, Liaoning, China

Purpose: To evaluate the effect of the recombinant adeno-associated virus (rAAV) vector that expresses human pigment epithelium-derived factor (hPEDF) on reducing blood–retinal barrier (BRB) breakdown in the experimental diabetic rat model.

Methods: Diabetes was induced by an intraperitoneal (i.p.) injection of streptozotocin (STZ) into 10-week-old male Wister rats. rAAV2-cytomegalovirus (CMV)-hPEDF was delivered into the right eyes by intravitreal injection on the first day after diabetes induction. The contralateral eyes received intravitreal injection of rAAV2-CMV-green fluorescent protein as the paired control. Gene delivery and expression of vascular endothelial growth factor (VEGF), occludin, and intercellular adhesion molecule-1 (ICAM-1) were determined with reverse transcriptase PCR or western blotting. BRB breakdown changes were quantified by measuring albumin leakage from retinal blood vessels after an intravenous (i.v.) injection of Evans blue albumin.

Results: Retinal transfection with the hPEDF gene construct led to sustained hPEDF gene expression for 6 months, significantly suppressing VEGF mRNA expression in the retina after 1, 3, and 6 months of diabetes induced by STZ compared with paired controls. Moreover, hPEDF dramatically reduced the levels of retinal ICAM-1 but increased the expression of occludin. Furthermore, BRB breakdown was much lower in hPEDF-injected diabetic animals in comparison with controls after 6 months.

Conclusions: A single intravitreal injection of rAAV2-CMV-hPEDF can relieve BRB breakdown in STZ-induced diabetic rats for 6 months. The effect is associated with downregulation of retinal VEGF mRNA and ICAM-1 expression and a reduction in the loss of retinal occludin induced by diabetes. The approach of gene transfer may reduce diabetic macular edema, providing long-term protection for diabetic patients at risk of macular edema.

Diabetic macular edema (DME) can lead to considerable vision loss in diabetic patients, especially in those with nonproliferative diabetic retinopathy (NPDR). An increase in vasopermeability, caused by the breakdown of the blood–retinal barrier (BRB), is a key factor of DME [1,2]. Although laser therapy has shown some effect on preventing partial visual loss, the current treatments for DME are far from satisfactory.

Vascular endothelial growth factor (VEGF), a hypoxia-induced angiogenic factor, is a potent vascular permeability factor that can cause hyperpermeability by inducing phosphorylation of tight junction proteins, such as occludin and zonula occludin-1 (ZO-1) [3,4]. Studies have shown that a high level of VEGF, found in the retina and vitreous of DME patients, coincided with BRB breakdown [5,6]; this suggests that VEGF may play an important role in DME formation. Recent studies have reported that pigment epithelium-derived factor (PEDF), a potent angiogenic inhibitor, was found in decreased amounts in the vitreous of diabetic retinopathy (DR) patients [7–10]. Vitreal injections of PEDF can suppress BRB breakdown and vascular permeability induced by VEGF [11], which implies that PEDF can take part in regulating vascular permeability. Based on the above, we hypothesize that an increase of retinal PEDF would antagonize VEGF and inhibit BRB breakdown in patients with diabetes.

Intravitreal injection is the best way to deliver PEDF. However, due to the short half-life of PEDF [12], multiple injections are required for treatment. However, repeated intraocular injections may cause increased risk of side effects, such as vitreous hemorrhage and retinal detachment, and may not be feasible depending upon the frequency of the injections required. Therefore, any approach that incorporates sustained drug delivery will improve efficacy and safety. Gene transfer offers an alternative means for this purpose. Recombinant adeno-associated virus vectors (AAV) have become potent gene delivery tools in a variety of animal models that mimic human retinal diseases because of a lack of pathogenicity, minimal immunogenicity, stable and efficient transfection, and the maintenance of high levels of transgene expression.

Correspondence to: Lei Chen, Department of Ophthalmology, First affiliated Hospital of China Medical University, Beiermalu 92#, Shenyang, China; Phone: 86-024-28851321; FAX: 86-024-28856251; email: yh7242@hotmail or leichen51@hotmail.com.
Prolonged transgene expression inhibition of choroidal neovascularization has been demonstrated after intraocular injection of AAV-mediated PEDF [13]. Herein, we used AAV vectors containing genes coding human PEDF to treat diabetic rats and to test the long-term effects of intravitreal injection of hPEDF on retinal permeability.

**METHODS**

**Animals:** Ten-week-old male Wister rats, weighing approximately 180–200 g, were purchased from the China Medical University Animal Resource Laboratory (Shenyang, China). Care, use, and treatment of all animals approved by the laboratory animal center and in this study were in strict agreement with the guidelines on the care and use of laboratory animals set forth by the laboratory animal center of China Medical University.

**Rats model of streptozotocin-induced diabetes:** Diabetes was induced by an intraperitoneal injection of streptozotocin (STZ; 60 mg kg\(^{-1}\) in 10 mmol l\(^{-1}\) of citrate buffer, pH 4.4; Sigma, Shanghai, China) into Wister rats that had been fasted for 12 h. Blood from tail vein was used for blood glucose level test 48 h after injection and blood glucose levels were monitored on a monthly basis. Only animals with blood glucose concentrations higher than 16.7 mmol/l were considered diabetic. The diabetic rats without complications from intravitreal injection (such as retinal detachment, hemorrhages, infection) were divided into three groups: 1 month (DM1), 3 months (DM3), and 6 months (DM6). Due to unexpected deaths, the final sample size of each group was 21 (4/25), 21 (4/25), and 20 (5/25), respectively.

**Intravitreal injection of vector:** Wister rats were intravitreally injected on the first day of diabetes (the animals had a blood glucose level higher than 16.7 mM). To avoid unnecessary effects on the retina induced by some nonexperimental factors, such as vectors themselves and the injection procedure, both eyes of rats were injected with vector. The rats were anesthetized with ketamine (Shandong Fangming Pharmaceutical Co, Ltd., Dongming, China; 80 mg kg\(^{-1}\)) by intraperitoneal injection, and the pupils dilated with tropicamide; then a 30-gauge needle on a Hamilton syringe was inserted into the vitreous cavity through the sclera just behind the limbus of the right eye, under microscopic control. Two microliters of rAAV2-cytomegalovirus (CMV)-hPEDF (1×10\(^{11}\) vector genomes ml\(^{-1}\); AGTC Gene Technology Company Ltd, Beijing, China) was injected into the vitreous of the right eye. The contralateral eye was injected with 2 µl of rAAV2-CMV-green fluorescent protein (GFP; 1×10\(^{11}\) vector genomes ml\(^{-1}\); AGTC Gene Technology Company Ltd) as the paired control. In the normal control group (CON), the right eyes were sham injected without infusing any drug as “treatment” and the left eyes were left intact.

**Histological evaluation of GFP expression:** The eyes with rAAV2-CMV-GFP injection were enucleated at 1, 3, and 6 months and then fixed in 4% paraformaldehyde for 1 h at 4 ºC. After washing thoroughly, the eyes were cut through the pars plana and the posterior sections with retinae were embedded in optimal cutting temperature tissue fluid (Maixin Bio, Led, Fuzhou, China) for sectioning. Serials of 10-µm frozen sections were observed with a fluorescence microscope (Olympus, BX51, Japan).

**Reverse transcriptase-PCR assessment:** Normal and diabetic rat eyes were enucleated at 1, 3, and 6 months, and the retinae were quickly collected and transferred into lysis buffer. Total RNA was isolated using a Trizol kit (Invitrogen Life Technologies, Shanghai, China), according to the manufacturer’s instructions. First-strand cDNA was synthesized from 0.1 µl of total RNA in 20 µl buffer containing 4 µl MgCl\(_2\), 1 µl oligo(dT) or random hexamer, 2 µl deoxy-ribonucleotide triphosphate (dTTP), 1 µl AMV reverse transcriptase, and 0.5 µl RNase inhibitor. Based on the manufacturer’s instructions, the reaction mixture was incubated at 30 ºC for 10 min, 42 ºC for 1 h, heat inactivated at 99 ºC for 5 min, 5 ºC for 5 min, and then the cDNAs pooled from two reactions with different primers. PCR was performed with 4 µl of pooled cDNA in 20 µl buffer containing 0.5 µl DNA polymerase, and 4 µl of the primers. The primer sequences for VEGF, hPEDF, and glyceraldehyde phosphate dehydrogenase (GAPDH; synthesis by Takara Biotechnology Co, LTD, Dalian, China) are as follows: VEGF: forward primer 5′-GCA CCC ACC ACA GAA GG-3′, reverse primer 5′-TGA ACG CTC CAG GAT TTA-3′, fragment length 416 bp; hPEDF, and glyceraldehyde phosphate dehydrogenase (GAPDH; synthesis by Takara Biotechnology Co, LTD, Dalian, China) are as follows: VEGF: forward primer 5′-GCA CCC ACC ACA GAA GG-3′, reverse primer 5′-TGA ACG CTC CAG GAT TTA-3′, fragment length 416 bp; GAPDH: forward primer 5′-ACC ACA GTC GAT GCC ACC-3′, reverse primer 5′-CTT CAT CCA AGT AGA TAT CC-3′, fragment length 310 bp; GAPDH: forward primer 5′-ACC ACA GTC GAT GCC ACC AC-3′, reverse primer 5′-TCC ACC CTG TTT CCG TA-3′, fragment length 452 bp. The reaction was cycled as follows: 2 min at 94 ºC; 30 cycles of 30 s at 94 ºC, 30 s at 57 ºC and 1 min at 72 ºC, and a final extension of 10 min at 72 ºC. PCR products were run on a 1.5% agarose gel.

**Western blot analysis:** Normal and diabetic rat eyes were enucleated at 1, 3, and 6 months and the retinae dissected free from surrounding tissue and then homogenized by sonication. The insoluble pellet was removed by centrifugation at 10,000× g for 15 min, and the protein concentration of the supernatant measured using a Coomasie brilliant blue protein assay (Jiancheng Bioengineering Institute, Nanjing, China). The soluble proteins (100 µg) were then resolved by sodium dodecyl sulfate PAGE (SDS–PAGE; 12% polyacrylamide gel for hPEDF, intercellular adhesion molecule-1 (ICAM-1) and occludin, 15% polyacrylamide gel for VEGF) and electrotransferred to a Hybond ECL nitrocellulose membrane (Amersham International, Piscataway, NJ). The membrane was blotted with polyclonal anti-hPEDF antibody (Boster Biotechnology LTD, Wuhan, China), polyclonal anti-VEGF antibody (Boster Biotechnology), anti-ICAM-1 antibody...
(1:500; Boster Biotechnology), and anti-occludin antibodies (1:1,000; Zymed Laboratory, San Francisco, CA). The concentrations of primary antibodies were 1:100. The membranes were stripped and re-immunostained with an antibody specific to β-actin (1:5,000 dilution; Sigma) as a normalization procedure. The densities of bands were measured with FluorChem version 2.0 imaging system (Alpha Innotech Corporation, San Leandro, CA) and normalized by β-actin as semiquantitation of protein.

**Measurement of blood–retinal barrier breakdown:** BRB breakdown was quantified by measuring albumin leakage from retinal blood vessels using the Evans blue albumin method, as described previously [14] with minor modifications. Briefly, Evans blue dye (Sigma) was dissolved in normal saline (30 mg ml⁻¹). The rats were anesthetized with ketamine (80 mg kg⁻¹) by intraperitoneal injection and the dye (45 mg kg⁻¹) injected over 10 s through the caudal vein. The rats were kept on a warm pad for 2 h to ensure complete dye circulation. Two minutes after the injection of Evans blue, 0.2 ml blood was drawn from tail vein to obtain the initial Evans blue plasma concentration. Subsequently, at 15-min intervals, 0.1 ml blood was drawn up to 2 h after injection to obtain the time-averaged Evans blue plasma concentration. At exactly 2 h after infusion, 0.2 ml blood was drawn to obtain the final Evans blue plasma concentration, after which the chest cavity was opened and the rats transcardially perfused via the left ventricle for 2 min (120 mmHg) with 37 °C 1% paraformaldehyde in citrate buffer (pH 4.2) to fix the retinae and clear excess dye from the blood vessels. Immediately after perfusion, the eyes were enucleated and the retinae dissected free from surrounding tissue. After thoroughly drying the retinae, they were weighed, and the Evans blue dye was extracted from the tissue by incubating each sample in 120 μl formamide (Sigma, ShangHai, China) for 18 h at 70 °C. The extract was centrifuged at 81,500× g for 45 min at 4 °C, and then the absorbance in 50 μl of the supernatant was measured at 620 nm and 740 nm. The concentration of Evans blue was calculated from a standard curve and normalized according to the retinal dry weight and expressed in ml plasma×g retinal dry wt⁻¹ h⁻¹.

**Statistical analysis:** All values were given as the mean ±standard deviation. One-way ANOVA and Pearson correlation analysis were used for statistical analyses. A p value of ≤0.05 was considered statistically significant. All data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL).

**RESULTS**

Expression of GFP in retina mediated by rAAV2 vector: GFP has the property of autoradiation of green fluorescence. Using a fluorescence microscope, GFP expression was evaluated after 1, 3 and 6 months of rAAV2-CMV-GFP injection. As shown in Figure 1, no hyperfluorescence signal was observed in normal retinae. After 1 month, hyperfluorescence signals were detected in the ganglion cell layer of retinae injected with recombinant adeno-associated virus vector-cytomegalovirus-green fluorescent protein. C, D: The area of fluorescence extended to most of the retinae after 3 months (C) and after 6 months (D), fluorescence signals had been detected in all retinae. The orientation of the sections was from superior to inferior. The bar is 200 μm, and magnification is 200×.

Figure 1. Expression of green fluorescent protein in retinae mediated by recombinant adeno-associated virus vector. A: No fluorescence signals were found in normal retinae. B: One month later, fluorescence signals were detected in the ganglion cell layer of retinae injected with recombinant adeno-associated virus vector-cytomegalovirus-green fluorescent protein. C, D: The area of fluorescence extended to most of the retinae after 3 months (C) and after 6 months (D), fluorescence signals had been detected in all retinae. The orientation of the sections was from superior to inferior. The bar is 200 μm, and magnification is 200×.
hyperfluorescence signals were detected in all retinae after 6 months.

**PEDF expression in the retina of diabetic rats after vector injection.** Expression of \( h \)PEDF mRNA in injected retinae was enhanced and increased over time. No expression were detected in the uninjected control rats. **B:** The protein expression of PEDF decreased in the paired control retinae but significantly increased in treated eyes (p<0.01) compared to paired control retinas or normal control eyes (p<0.01). Values of treatment were compared to that of normal control *p value <0.05, ** p value<0.01. Values of treatment were compared to that of paired control, # p value <0.01. Abbreviations: DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months, CON represents normal control group, CONf represents sham-injected normal control group, t represents treatment.

### Table 1. Expression of hPEDF mRNA

| Groups    | Paired control | Treatment |
|-----------|----------------|-----------|
| CON       | 0              | 0         |
| DM1       | 0              | 0.34±0.03 |
| DM3       | 0              | 0.47±0.04*|
| DM6       | 0              | 0.62±0.05*|

The asterisk indicated compared to 1 month p value<0.05. Abbreviations: CON represents normal control group, DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months.
Figure 3. Expression of vascular endothelial growth factor in retinae after intravitreous injection. A: Vascular endothelial growth factor (VEGF) mRNA in paired control retinae increased with time to almost twice that in the normal control eyes after 6 months. Similarly, the amount of VEGF mRNA in the retinae of all treatment groups was statistically higher than the amount in normal retinae but was significantly lower than the amount in the respective paired control eyes (p<0.01). B: The expression of VEGF protein in treated retinae paralleled the expression of VEGF mRNA. Values of treatment were compared to that of normal control * p value <0.05, ** p value<0.01. Values of treatment were compared to that of paired control # p value <0.01. Abbreviations: DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months, CON represents normal control group, CONf represents sham-injected normal control group, t represents treatment.
6 months after the injection of rAAV2-CMV-hPEDF. Bands about 310 bp corresponding to the hPEDF mRNA primer were not detected in normal eyes and paired control eyes, while hPEDF mRNA primer expression was identified in the retinae of rAAV2-CMV-hPEDF injected eyes and significantly increased over time (p<0.05 n=13, 13, 12, respectively; Figure 2A), reaching a maximum at the 6 months.

Western blot analysis also showed that the expression of PEDF increased significantly in vector-injected eyes compared to the paired control eyes (p<0.01), which showed a decreased PEDF, and normal control eyes (p<0.01). These results were consistent with findings on the expression of PEDF at the mRNA level (Figure 2B, Table 1).

**Table 2. Expression of VEGF in the retinae**

| Groups | Paired control | Treatment |
|--------|----------------|-----------|
| CON    | 0.25±0.04      | 0.28±0.04 |
| DM1    | 0.52±0.04**    | 0.37±0.03/* |
| DM3    | 0.63±0.08**    | 0.38±0.02/* |
| DM6    | 0.86±0.08**    | 0.41±0.09/* |

Values of treatment were compared to that of normal control * p value <0.05, ** p value<0.01. Values of treatment were compared to that of paired control # p value <0.05, ## p value<0.01. Abbreviations: T represents treatment, CON represents normal control group, DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes6 months, VEGF represents vascular endothelial growth factor, PEDF represents pigment epithelium-derived factor, VEGFp represents VEGF protein, PEDFp represents PEDF protein.

**Table 3. Expression of ICAM-1 and Occludin in the retinae**

| Groups | Paired control | Treatment |
|--------|----------------|-----------|
| CON    | 0.14±0.01      | 0.15±0.01 |
| DM1    | 0.40±0.02*     | 0.31±0.01/* |
| DM3    | 0.65±0.02*     | 0.36±0.01/* |
| DM6    | 0.70±0.02*     | 0.44±0.03/* |

*Values of treatment were compared to that of normal control, p value <0.05. #Values of treatment were compared to that of paired control, p value <0.01. Abbreviations: PC represents paired control, T represents treatment, CON represents normal control group, DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months, ICAM-1 represents intercellular adhesion molecule-1.

6 months after the injection of rAAV2-CMV-hPEDF. Bands about 310 bp corresponding to the hPEDF mRNA primer were not detected in normal eyes and paired control eyes, while hPEDF mRNA primer expression was identified in the retinae of rAAV2-CMV-hPEDF injected eyes and significantly increased over time (p<0.05 n=13, 13, 12, respectively; Figure 2A), reaching a maximum at the 6 months.

Western blot analysis also showed that the expression of PEDF increased significantly in vector-injected eyes compared to the paired control eyes (p<0.01), which showed a decreased PEDF, and normal control eyes (p<0.01). These results were consistent with findings on the expression of PEDF at the mRNA level (Figure 2B, Table 1).

**rAAV2-CMV-hPEDF injections downregulated expression of VEGF:** To assess the relationship between VEGF and PEDF, we analyzed the expression of VEGF in retinae, at both mRNA and protein levels, at 1, 3, and 6 months after vector injection, by using RT–PCR and western blots. VEGF mRNA in paired control retinae increased with time to almost twice that in the normal control eyes after 6 months. Similarly, the amount of VEGF mRNA in the retinae of all treatment groups was statistically higher than that in the normal retinae (p<0.05, Figure 3A) but was significantly lower than that in the respective paired control eyes (p<0.01). Furthermore, a significant negative correlation between the expression of VEGF mRNA and PEDF mRNA (r=-0.732, p<0.01) was observed.

The expression of VEGF protein in rAAV2-CMV-hPEDF-injected retinae showed similar trends to that of VEGF mRNA (Figure 3B), which indicated that overexpression of hPEDF in the retina downregulated the expression of VEGF at both mRNA and protein levels. In the treated retinae, the value of VEGF against PEDF was nearly equal to that in the normal control and was lower relative to the paired control retinae. However, the ratio of VEGF:PEDF in paired control retinae increased with time to almost eight times that of the normal control’s value after 6 months (Table 2).

**hPEDF upregulated retinal occludin but downregulated retinal ICAM-1:** Western blot was used to assess the effect of hPEDF on occludin and ICAM-1 protein levels after retinal hPEDF gene transfection. Although retinal occludin in treated eyes did not differ significantly from the levels of paired control eyes after 1 month, at 3 and 6 months its level in rAAV2-CMV-hPEDF-injected eyes increased significantly compared with paired control eyes (Figure 4) and reached levels similar to that seen in the normal eyes at 6 months. In
contrast, the retinal occludin level in paired control eyes was significantly lower than that in the treatment and normal eyes. On the other hand, the expression of ICAM-1 increased in paired controls and treated retinae compared with its expression in normal eyes (p<0.05). Its level remained significantly lower in the injected retinae (p<0.01) compared with paired control eyes. There was a significant negative correlation between ICAM-1 and occludin (r=-0.754, p<0.01) .

rAAV2-CMV-hPEDF injections suppressed blood–retinal barrier breakdown: To determine the permeability of the retinal vasculature in diabetic rats and the effect of PEDF on the BRB, we intravenously injected rats with Evans blue albumin on the last day of months 1, 3, and 6. Our standard curves shown in Figure 5A confirm the reliable linear relationship between background-subtracted absorbance (620–740 nm) and Evans blue concentration in formamide from 1 to 80 μg ml\(^{-1}\) (r=0.999, regression equation y=0.0038×−0.003).
Leakage from the retinal vasculature became more and more severe with the progression of diabetes in the paired control eyes (Figure 5B) and it reached a maximum by the month 6 (50.48±13.79) with a fourfold increase compared with that in normal control eyes (14.04±4.54, p<0.01). The damage to the BRB was less severe in the treatment group compared with the paired control group, especially at the 3 and 6 months (p<0.05). Nevertheless, Evans blue levels in the treatment group were all significantly higher than levels seen in normal control retinae (p<0.05).

DISCUSSION

Our study demonstrated that single intravitreal injection of rAAV-PEDF relieved BRB breakdown in STZ-induced diabetic rats for 6 months. The effect was associated with the downregulation of retinal VEGF mRNA and ICAM-1 expression and concomitant upregulation of occludin
expression. rAAV₂-CMV-hPEDF partly ameliorated the retinal VEGF/PEDF imbalance and thus reduced the vascular permeability and subsequently restored BRB.

Diabetic macular edema is a common pathological feature in DR and responsible for vision loss. BRB breakdown, a characteristic sign of early DR, and the subsequent increase in vascular permeability are believed to play major roles in the development of DME and progression of DR. To date, the exact mechanisms underlying the pathogenesis of the changes of BRB in DR are unclear.

Accumulating clinical evidence has suggested that VEGF plays an important role in DME in early diabetes [10,15,16]. VEGF is a potent vascular permeability factor [17], which significantly increased endothelial permeability (approximately twofold) after 24 h co-incubation with retinal capillary endothelial cells [18], and caused BRB breakdown after sustained intravitreal release in rabbits [19,20]. Previous studies have shown that the levels of VEGF and VEGF receptor were higher in DR [21,22]. In the early stages of STZ-induced diabetes in rats, retinal VEGF mRNA levels dramatically increased and were correlated with retinal vascular permeability. However, this early BRB breakdown was successfully prevented by VEGF TrapA40, a soluble VEGF receptor Flt/Fc [23]. In this study, we have confirmed the association between the increases in retinal VEGF levels and BRB breakdown in animals with induced diabetes, suggesting that the overexpression of retinal VEGF induces BRB breakdown.

PEDF is an endogenous angiogenic inhibitor in the eye and can counterbalance the angiogenic effect of VEGF and suppress neovascularization in PDR and age-related macular degeneration (AMD) [24–27]. Clinical studies have shown that decreased expression of PEDF in the retina and vitreous was associated with DME [10]. High levels of PEDF might reduce vascular leakage induced by VEGF [11] or diabetes [18], suggesting that PEDF is involved in the regulation of vascular permeability. Therefore PEDF therapy may be effective not only for PDR but also for DME.

We consider an ideal therapeutic strategy for DME treatment would be to develop an approach involving single administration of vectors to sustain the long-term expression of a suitable therapeutic gene. rAAV vectors are highly efficient gene delivery systems that can facilitate long-term transduction [13,24]. Although AAV-PEDF has been used to inhibit retinal and choroidal neovascularization induced by laser or hypoxia [13,27], to our knowledge, this is the first time for the application of AAV-PEDF in eyes of STZ-induced diabetic animals. Indeed, our study has shown that PEDF expression in the retina lasted for 6 months after rAAV₂-CMV-hPEDF injection, which potentially enables clinicians to avoid repeated intravitreal injections. In addition, we demonstrated that intravitreal injections of rAAV₂-CMV-hPEDF suppressed BRB breakdown by downregulating the expression of VEGF in diabetic rats. In our study, retinal VEGF mRNA/protein expression and BRB breakdown decreased in rAAV₂-CMV-hPEDF-transfected eyes compared with the contralateral control eyes injected with rAAV₂-CMV-GFP. The retinal balance of VEGF/PEDF was partially corrected in these diabetic rats by downregulation of VEGF mRNA expression in the retina, which is consistent with previous reports on the reduction of vascular leakage via the blockade of VEGF with PEDF [11,18]. The exact mechanism(s) by which PEDF reduces vascular leakage through inhibition of VEGF production is still under investigation.

VEGF-mediated upregulation of ICAM-1, an adhesion receptor for leukocytes, may contribute to the observed retinal vascular changes, such as vascular leakage and local nonperfusion in early diabetic retinopathy [28,29]. This conclusion is based on two lines of evidence. First, previous studies have demonstrated that the expression of both retinal VEGF mRNA [23] and ICAM-1 [30] were upregulated in rodent models of diabetic retinopathy and ICAM-1 levels were decreased by suppressing VEGF activity associated with a decrease in BRB breakdown and leukostasis [31]. Second, studies in nondiabetic rats found that retinal ICAM-1 was upregulated in response to VEGF [32] and the overexpression of ICAM-1 mRNA induced by VEGF via the phospholipase c/nuclear factor-kB (PLC/ NF-kB) pathway in endothelial cells [33]. Inhibition of ICAM-1 activity significantly suppressed VEGF-induced hyperpermeability and leukostasis. These data suggest that ICAM-1 is a crucial mediator of the VEGF effect on vascular permeability [34]. In our study, retinal ICAM-1 decreased in the eyes receiving rAAV₂-CMV-hPEDF injection, suggesting that PEDF decreased ICAM-1 expression in the diabetic retina.

The tight junctions between retinal vascular endothelial cells constitute an essential structural component of the BRB. We observed that the levels of occludin, a barrier protein, decreased by around 50% to 60% between 3 and 6 months after induction of diabetes, which is consistent with the results of Antonetti and colleagues [35]. VEGF not only decreases occludin expression [18] but also stimulates its phosphorylation and redistribution [36,37] by activating the phosphatidylinositol 3-kinase/protein kinase C (PKC) isoform pathway [38], which subsequently induces elevated vascular permeability. This implies that a lowering and redistribution of retinal occludin induced by overexpression of VEGF may be responsible for BRB breakdown in early DR [35]. Ho and coworkers [39] reported that PEDF prevented the redistribution of occludin in retinal pigment epithelium (RPE) cells from being damaged by oxidants. Our study showed a significant negative relationship between retinal VEGF and occludin. Intravitreal injection of rAAV₂-CMV-hPEDF significantly increased retinal occludin expression in STZ-induced diabetic rats, with a concomitant reduction in retinal vascular permeability. We suggest, therefore, that
hPEDF may reduce vascular leakage partly by preserving retinal occludin content in these rats through inhibition of VEGF. These results suggest that transgenic expression of rAAV2-CMV-hPEDF may be a useful strategy for long-term preventive or adjunctive therapy for DME.

Although the findings reported here have important clinical implications for DR therapy, the safety issues and immune response induced by vectors should be studied further. Recently, Li and colleagues found that intravitreal injection of AAV vectors in mice generated a humoral immune response against AAV capsid, which suppressed vector expression upon re-administration via the same route into the partner eye [40]. Application of an AAV vector with intravitreal injection would be limited if a similar immune response is found in humans. However, this conclusion is worthy of further investigation because the vitreous cavity and subretinal space are immune-privileged sites [41], BRB isolates them from the main circulation, and findings in animals cannot be simply extrapolated because humans possess a more complicated immune system. Many factors could affect the immune response against AAV-mediated ocular gene transfer in diabetic eyes, such as vitreous hemorrhages and neovascularization, which compromise the immune privilege of the eye. Further studies need to be performed to address these issues.

ACKNOWLEDGMENTS
The authors thank Ning-Ning Liu MD for excellent technical support.

REFERENCES
1. Do carmo A, Ramos P, Reis A, Proenca R, Cunha-vaz JG. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 1998; 67:569-75. [PMID: 9878219]

2. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol 1989; 134:231-5. [PMID: 2916645]

3. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998; 111:1853-65. [PMID: 9625748]

4. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludin 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274:23463-7. [PMID: 10438525]

5. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74:819-25. [PMID: 8606491]

6. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995; 27:48-52. [PMID: 7956559]

7. Ogata N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, Matsumura M. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001; 132:378-82. [PMID: 11530051]

8. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreal levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002; 134:348-53. [PMID: 12208245]

9. Spranger J, Osterhoff M, Reimann M, Möhlig M, Ristow M, Francis MK, Cristofalo V, Hammes HP, Smith G, Boulton M, Pfeiffer AF. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50:2641-5. [PMID: 11723044]

10. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H, Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113:294-301. [PMID: 16406543]

11. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004; 101:6605-10. [PMID: 15096582]

12. Amaral J, Fariss RN, campos MM, Robison WG Jr, Kim H, Lutz R, Becerra SP. Transcleral-RPE permeability of PEDF and ovalbumin protein: implication for subconjunctival protein delivery. Invest Ophthalmol Vis Sci 2005; 46:4383-92. [PMID: 16303924]

13. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KL, Raisler BJ, Hauswirth WW, Campochiaro PA. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43:1994-2000. [PMID: 12037010]

14. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001; 42:789-94. [PMID: 11222542]

15. Funatsu H, Yamashita H, Ikeda T, Nakashima Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002; 133:537-43. [PMID: 11931788]

16. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006; 82:798-806. [PMID: 16324700]

17. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrin Rev 2004; 25:581-611. [PMID: 15294883]

18. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20:323-5. [PMID: 16368716]

19. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the
blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64:505-17. [PMID: 9227268]

20. Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest Ophthalmol Vis Sci 2000; 41:1561-9. [PMID: 10798677]

21. Hames HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47:401-6. [PMID: 9519746]

22. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacke SA, Cooper ME. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78:1017-27. [PMID: 9714188]

23. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hasseissian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42:2408-13. [PMID: 11527957]

24. Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1–3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002; 99:8909-14. [PMID: 12072560]

25. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, Davarya S, Tong P, Gehlbach P, Pearlman J, Crabb JW, Aiello LP, Campochiaro PA, Zack DJ. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43:821-9. [PMID: 11867604]

26. Stellmach V, Crawford SE, Zhou W, Bouch N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98:2593-7. [PMID: 11226284]

27. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43:2428-34. [PMID: 12091447]

28. Miyamoto K, Khorosfo S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000; 156:1733-9. [PMID: 10793084]

29. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998; 47:1953-9. [PMID: 9836530]

30. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 2003; 44:5410-6. [PMID: 14638745]

31. Ho TC, Yang YC, Cheng HC, Wu AC, Chen SL, Tsao YP. Pigment epithelium-derived factor protects retinal pigment epithelium from oxidant-mediated barrier dysfunction. Biochem Biophys Res Commun 2006; 342:372-8. [PMID: 16483542]

32. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW. Intracocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008; 14:3561-8. [PMID: 11006253]

33. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Bio 2004; 36:1206-37.

34. Jiang LQ, Joquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993; 34:3347-54. [PMID: 8225870]

The print version of this article was created on 9 November 2010. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.